What Is First Tracks Biotherapeutics, I (TRAX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, First Tracks Biotherapeutics, I's intrinsic value is estimated at $12.34, suggesting the stock is overvalued at its current price of $36.21. With 7 out of 7 models flagging downside (-65.9% average return), the market may be pricing in unsustainable growth. Notably, First Chicago sees the most upside at -35.9% (fair value: $23.21), while Dynamic NAV is the most conservative at -89.8% ($3.69). The spread between these extremes — +53.9% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About TRAX?
7 of 13 models are currently active for TRAX. All 7 active models suggest the stock trades above fair value. The Bayesian DCF estimates TRAX's intrinsic value at $4.25, implying -88.3% downside from the current price. See which stocks rank higher →
How Does TRAX Rank in Pharmaceutical Preparations?
Among 438 Pharmaceutical Preparations stocks, TRAX ranks #435 by Quality of Company score. CirclFi's QOC score of 2.0/10 evaluates 32 fundamental signals. A score of 2.0 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, First Tracks Biotherapeutics, I competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is TRAX a Value Trap?
The Value Trap algorithm is not active for TRAX. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for First Tracks Biotherapeutics, I. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, First Tracks Biotherapeutics, I is rated at 2.0/10. This weak-tier score exhibits fundamental weaknesses that warrant careful scrutiny.
The gap between the most bullish and bearish model spans +53.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every TRAX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across TRAX's 7 active models, average confidence is 2%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad